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Traumatic brain injury (TBI) results in long-lasting cognitive impairments for which there is
currently no accepted treatment. A well-established mouse model of mild to moderateTBI,
lateral fluid percussion injury (FPI), shows changes in network excitability in the hippocam-
pus including a decrease in net synaptic efficacy in area CA1 and an increase in net synaptic
efficacy in dentate gyrus. Previous studies identified a novel therapy consisting of branched
chain amino acids (BCAAs), which restored normal mouse hippocampal responses and
ameliorated cognitive impairment following FPI. However, the optimal BCAA dose and
length of treatment needed to improve cognitive recovery is unknown. In the current study,
mice underwent FPI then consumed 100 mM BCAA supplemented water ad libitum for 2,
3, 4, 5, and 10 days. BCAA therapy ameliorated cognitive impairment at 5 and 10 days dura-
tion. Neither BCAA supplementation at 50 mM nor BCAAs when dosed 5 days on then
5 days off was sufficient to ameliorate cognitive impairment. These results suggest that
brain injury causes alterations in hippocampal function, which underlie and contribute to
hippocampal cognitive impairment, which are reversible with at least 5 days of BCAA treat-
ment, and that sustaining this effect is dependent on continuous treatment. Our findings
have profound implications for the clinical investigation of TBI therapy.
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INTRODUCTION
Traumatic brain injury (TBI) is a worldwide problem and a major
cause of disability in US. The annual incidence of TBI is over 1.2
million people and approximately 50,000 TBI-related deaths occur
each year (1). Costs from TBI exceed more than $37 billion per
year in US alone, due in part to the over 5 million people with
chronic disabilities resulting from TBI (2, 3). There are currently
no accepted therapies for the cognitive deficits attributed to TBI
(4, 5).
A well-established mouse model of mild to moderate TBI, lat-
eral fluid percussion injury (FPI), produces deficits similar to those
reported after human TBI, including memory deficits, patholog-
ical gliosis, and ionic perturbations (6, 7). The hippocampus, a
brain structure vital to learning and memory, is particularly vul-
nerable to TBI. Optimal hippocampal function requires a delicate
balance between neuronal excitation and inhibition. This balance
determines net synaptic efficacy in the hippocampus, which is
profoundly and chronically altered after FPI in a region-specific
manner (8–12). In the CA1 region of the hippocampus, FPI causes
a decrease in network excitability, while in the dentate gyrus
network excitability is increased (8).
The conditioned fear response (CFR), a widely accepted behav-
ioral test of hippocampal function (13), is measured by the extent
of “freezing” (animal remains motionless) when the animal is
returned to the location in which it previously received an aversive
foot shock. Mild to moderate FPI causes deficits in fear con-
ditioning, which were shown previously to reflect hippocampal
dysfunction (14).
Recent studies in our laboratory demonstrated that hippocam-
pal concentrations of the branched chain amino acids (BCAAs:
leucine, isoleucine, and valine) are reduced after TBI and treat-
ment with these amino acids restored cognitive function to levels
comparable to non-injured mice (15). Furthermore, BCAA ther-
apy mitigated injury-induced deficits in maintaining wakefulness
and also restored electroencephalography (EEG) rhythms asso-
ciated with normal wakefulness, in mice after TBI (16). These
animal data are consistent with studies in humans demonstrat-
ing improved disability rating scale scores after treatment with
intravenous BCAAs in adults recovering from severe TBI (17, 18).
BCAAs are essential amino acids (i.e., they are acquired solely
through dietary intake) and are precursors for the de novo synthe-
sis of the neurotransmitters glutamate and GABA (19, 20). They
are also a major source of intermediates for the citric acid cycle,
and BCAA supplementation been used to treat diseases associated
with alterations in their metabolism [reviewed in Ref. (17, 21)].
Plasma and hippocampal levels of the BCAAs are reduced after
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TBI (15, 22, 23), due perhaps in part to the metabolic disturbances
associated with the brain injury. While full details of the mecha-
nism by which BCAAs act is not currently known, the BCAAs may
improve hippocampal function after TBI by restoring releasable
pools of glutamate and GABA. Consistent with this hypothesis,
BCAA treatment restored normal hippocampal stimulus-evoked
responses in vitro when BCAAs were bath applied to hippocampal
slices prepared from injured animals, and also when hippocampal
slices were prepared from brain-injured mice that had been treated
with BCAAs in their drinking water [100 mM BCAA supple-
mented drinking water for 5 days (15)]. The current experiments
were designed to (1) determine the minimum treatment time and
dosage of BCAA therapy necessary to restore normal behavior, and
(2) determine if the functional improvements produced by BCAA
therapy are sustained after therapy is stopped.
MATERIALS AND METHODS
ANIMALS
All experiments were performed on 5- to 7-week-old, 20–25 g,
male C57BL/J6 mice (Jackson Laboratory). The animals were
housed in a room that was maintained at an ambient tempera-
ture of 23± 1°C with a relative humidity of 25± 5% and that was
on an automatically controlled 12-h light/12-h dark cycle (light
on at 07:00 hours, illumination intensity ≈100 lux). The animals
had free access to food and water. Every effort was made to min-
imize the number of animals used and any pain and discomfort
experienced by the mice. Animal experiments were performed in
accordance with the guidelines published in the National Institutes
of Health Guide for the Care and Use of Laboratory Animals and
were approved by the Children’s Hospital of Philadelphia Ani-
mal Care and Use Committee in accordance with international
guidelines on the ethical use of animals.
FLUID PERCUSSION INJURY
Mice were anesthetized using a combination of ketamine
(2.6 mg/kg) and xylazine (1.6 mg/kg) and placed in a stereotaxic
frame (Stoelting). A midline incision in the scalp was made and
a 3 mm diameter, 1 mm height disk was glued to the skull using
the tissue glue, Vetbond. Between lambda and bregma, lateral to
the sagittal suture on the right side, a trephine (3 mm diameter)
was used to perform a craniectomy. A luer-loc needle hub with a
3 mm diameter was secured to the skull around the opening using
Loctite glue and dental cement. The luer-loc was filled with saline
and capped for 24 h. The next day, animals underwent lateral FPI.
They were anesthetized using 2% isoflurane, the cap was removed
and the luer-loc was filled with saline to ensure the fluid pulse was
consistent and continuous, and free from air bubbles. The luer-loc
was then secured to the FPI device (Department of Biomedical
Engineering, Virginia Commonwealth University, Richmond, VA,
USA) and a fluid pulse of 20 ms was administered. The injury pres-
sure was measured via an oscilloscope attached to the injury device
and for all animals was in a range of 1.8–2.1 atm. After recov-
ering on a heating pad, the luer-loc was removed and the scalp
was sutured. Mice were returned to their home cage for recov-
ery. Animals were allowed to recover for 48 h prior to initiating
treatment.
STUDY DESIGN
Mice were housed individually and in all experiments except the
gavage administration experiments drank ad libitum either BCAA
supplemented water or untreated water. In the time course exper-
iments, mice were treated with BCAAs for 2, 3, 4, 5, or 10 days as
indicated (Figure 1A). In the gavage administration experiments,
mice received oral gavage once daily with a solution containing
BCAAs, or untreated water, for 3 or 5 days in order to compare
ad libitum consumption of BCAAs with oral gavage delivery of a
more precisely delivered amount. In the duration of action experi-
ments, mice received 100 mM BCAA supplemented drinking water
for 5 days, as in the initial time course experiments, but then
received 5 days of untreated drinking water (Figure 1B) prior to
behavioral testing. In the supplement concentration experiments,
mice received drinking water that was either 50 or 100 mM in
BCAAs (Figure 1C).
BCAA TREATMENT
Drinking water in the treatment groups was supplemented with
100 or 50 mM concentrations of each of leucine, isoleucine, and
valine and consumed ad libitum (time course, duration of action,
and supplement concentration experiments). Control treatment
consisted of drinking untreated tap water. The amount of drink-
ing water remaining in the bottle was measured each day, and fresh
BCAA supplemented water (treatment groups) or fresh untreated
water (control groups) was replaced each week. Mice drank on
average 3–5 mL of solution per day and it has been previously
shown that BCAAs do not affect body weight (15). A similar
dose of BCAA’s (0.26 g BCAAs in equimolar amounts/kg of mouse
weight) was delivered via oral gavage once daily (gavage volume
for a typical 25 g mouse was 170µL) per treatment day in the
gavage administration experiments.
CONDITIONED FEAR RESPONSE
After recovery from FPI each animal was handled daily for 3 min
over the 3 days leading up to fear conditioning (except for the
animals tested at day 2, which were handled for only 2 days prior
to testing). On day prior to CFR testing, mice were placed in the
fear conditioning chamber (Med Associates, St. Albans, VT, USA)
for a total of 3 min. After 2 min and 28 s in the chamber, animals
received a 2-s shock of 1.05 mA intensity via the metal bars com-
prising the floor of the box. Animals remained in the box for an
additional 30 s before being removed and placed back into the
home cage. The box was cleaned with 70% ethanol in between
the training of each animal. Twenty-four hours later, mice were
returned to the fear-conditioning box for a total of 5 min. Obser-
vation of freezing behavior occurred every 5 s for the entire 5 min,
for a total of 60 observations. Freezing percentage was calculated
by dividing the number of observed instances of freezing by the
total number of observations. Thus, a lower freezing percentage is
indicative of impaired contextual memory.
STATISTICAL PROCEDURES
Data collection and analysis were performed blinded to experi-
mental group. Statistical analyses were performed using GraphPad
Prism (San Diego, CA, USA). Data were tested to ensure normal-
ity, and subsequently analyzed using either two-tailed Student’s
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FIGURE 1 | Experimental timeline. (A)To determine the effect of
treatment duration on cognitive recovery, injured mice received BCAA
supplemented drinking water or untreated water for varying lengths of
time. Vertical arrows indicate times for injury, treatment onset, and
conditioned fear testing. (B)To determine the duration of action of BCAA
treatment, mice receiving 10 consecutive days of BCAA therapy were
compared to mice receiving 5 days of BCAA supplemented water followed
by 5 days of untreated water. (C)To determine the effective concentration
of BCAA supplemented water, mice consumed 5 days of either 100 or
50 mM BCAA supplemented water or untreated water. Abbreviations: FPI,
fluid percussion injury; CFR, conditioned fear response, BCAAs, branched
chain amino acids.
t -tests, two-way ANOVA with Bonferroni post hoc tests, or one-
way ANOVA followed by Dunnett’s post hoc tests if the F values
reached statistical significance (P < 0.05). Statistical significance
was defined at the P < 0.05 confidence level. Power analyses
were performed to determine group sizes. In previous studies,
the response within each subject group was normally distrib-
uted with a SD of ≈25%. If the true difference in the exper-
imental and control means is ≈50%, we calculated the need
to study at least five subjects per group to be able to reject
the null hypothesis that the population means of the experi-
mental and control groups are equal with probability (power)
0.8. The Type I error probability associated with this test of
this null hypothesis is 0.05. All data are presented as group
means± SEM.
RESULTS
BCAA THERAPY RESTORES CONDITIONED FEAR RESPONSES IN
BRAIN-INJURED MICE
Previous research from our lab demonstrated that freezing behav-
ior in the CFR is impaired after mild to moderate FPI, and
restored with 5 days of BCAA therapy (15). However, the mini-
mum required treatment time, the minimum effective dose, and
the duration of action of BCAA treatment are still unknown. As
all of these values are necessary for the development of a translat-
able therapeutic regimen, they were determined in the following
experiments.
In the time course experiments, mice consumed BCAA sup-
plemented drinking water or untreated water ad libitum for 2,
3, 4, 5, or 10 consecutive days before undergoing CFR testing
(Figure 1A). All animals tested demonstrated freezing. Freez-
ing in individual animals ranged from 6.7% (measured 2 days
after injury, in the untreated group) to 68.3% (measured 10 days
after injury, in the 10-day BCAA treated group). As a group,
injured mice that received BCAA treatment showed a significantly
greater freezing response on average compared to untreated FPI
mice when treatment was delivered for 5 or 10 consecutive days
(Figure 2A; F = 18.12, P < 0.0001, two-way ANOVA; *P < 0.05,
Bonferroni post hoc tests; untreated n’s, 2 through 10 days: 4, 8, 7,
16, 12; treated n’s, 2 through 10 days: 8, 7, 8, 15, 5). Although
BCAA treatment also increased freezing in mice treated for 2,
3, and 4 days, those improvements were not statistically signifi-
cant. These results suggest that BCAA supplementation improves
cognitive recovery if consumed for at least five consecutive days
after injury.
We also measured fear conditioning in a set of naïve ani-
mals in order to assess the extent of the cognitive recovery in
the BCAA treated groups, which showed significant improvement
(Figure 2A). Freezing in naïve animals was 38.8± 3.8% (n= 10),
and was not significantly different from freezing in the 5-day
(n= 16) or 10-day (n= 5) BCAA treated groups (P = 0.394 for
naive, 5- and 10-day BCAA treated mice, one-way ANOVA). In
summary, treatment with BCAAs for 5 or 10 days restored freezing
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FIGURE 2 |Time course of BCAA treatment required to restore
conditioned fear response. (A) BCAA supplemented water (100 mM,
black bars) or plain water (open bars) were offered ad libitum to
brain-injured mice for 2, 3, 4, 5, or 10 days. Conditioned fear responses, as
measured by the percentage of observations in which the animal
demonstrated freezing behavior, were recorded for each animal. All animals
in all treatment groups demonstrated at least some freezing, and the
average level of freezing was calculated for each group. Freezing was
restored to normal levels at the 5- and 10-day time points (*P <0.05).
Conditioned fear responses in naïve animals were not significantly different
from conditioned fear responses in either the 5- or 10-day BCAA treated
groups. (B)Water containing BCAAs (0.26 g/kg) or untreated water was
administered via oral gavage once daily for 3 or 5 days. Significant
improvement in freezing behavior was observed following five consecutive
days of gavage BCAA treatment (*P <0.05), but not after 3 days of
treatment, and 5-day gavage results were not significantly different from
the 5-day supplemented water results. Abbreviations: FPI, fluid percussion
injury; BCAAs, branched chain amino acids.
behavior in injured mice to normal levels, indicating complete
recovery of fear conditioning after treatment with BCAAs.
To compare the efficacy of treatment with BCAA supplemented
drinking water to treatment with a more precisely known dose of
BCAAs, mice were given BCAAs via oral gavage. Mice underwent
FPI surgery as above, and then 2 days following injury began daily
treatment with BCAAs via oral gavage for 3 or 5 days at a dose
chosen to replicate our estimate of the dose received via BCAA
supplemented drinking water (0.26 g BCAAs/kg of mouse weight).
Injured mice receiving BCAAs via oral gavage for 5 days showed
significantly greater freezing than FPI mice receiving untreated
water via oral gavage (Figure 2B; t = 2.752, P = 0.0175, Student’s
two-tailed t -test). Freezing in the 5-day gavage mice was not signif-
icantly different from freezing from the 5-day BCAA supplemented
drinking water mice (t = 0.419, P = 0.679, Student’s two-tailed t -
test; 5-day gavage: 32.9± 3.2%, n= 15; 5-day supplemented water:
30.8± 2.7%, n= 8). The gavage results are consistent with the
ad libitum supplementation findings that BCAA therapy at these
doses requires at least 5 days of continuous administration in order
to significantly improve cognitive recovery, and those 3 days of
therapy are not sufficient. The gavage results also suggest that
treatment with a BCAA dose of 0.26 g/kg is equivalent to treatment
with ad libitum 100 mM BCAA supplemented drinking water.
To examine the duration of action of BCAA treatment, a sepa-
rate cohort of mice were given 100 mM BCAA supplemented water
for 5 days followed by for 5 days of untreated drinking water (i.e.,
5d+|5d− treatment) (Figure 1B). Freezing in the TBI 5d+|5d−
mice was significantly lower than freezing in TBI 10d+mice, and
was not significantly different from freezing in the untreated TBI
10d−mice (Figure 3A; F = 3.67, P = 0.0421, TBI 5d+|5d− n= 8,
TBI 10d+ n= 5, TBI 10d− n= 8, one-way ANOVA; P < 0.05,
Dunnett’s post hoc tests). In other words, the TBI 5d+|5d− group
reverted back to the injured phenotype. These data suggest that
BCAA treatment lasting only 5 days does not provide long-lasting
benefits, and that ongoing BCAA treatment is needed to maintain
optimal hippocampal function.
To determine if a lower concentration of BCAA supplemented
water could also ameliorate cognitive impairment after injury, a
separate group of animals received only 50 mM of BCAAs ad libi-
tum for 5 days, and were compared to the injured animals that
received 100 mM BCAA supplemented drinking water for 5 days
(Figure 1C). Injured mice in the 50 mM group showed signifi-
cantly less freezing than mice in the 100 mM group, and were not
significantly different from untreated injured mice (Figure 3B;
F = 6.295, P = 0.0045, injured untreated n= 16, 100 mM n= 15,
50 mM n= 8, one-way ANOVA, Tukey’s post hoc tests). These
data indicate that for treatment of injured mice with BCAA sup-
plemented drinking water, 50 mM BCAAs is not a high enough
concentration to restore normal fear conditioning.
Overall, the results above show that BCAA treatment restores
normal hippocampal functioning after brain injury as assessed by
contextual fear conditioning. Although treatment with BCAAs for
5 days does not permanently restore normal hippocampal func-
tion, continuous BCAA treatment for at least 5 days does restore
and maintain normal hippocampal responses.
DISCUSSION
Previous data from our laboratory demonstrated that BCAA sup-
plementation restores contextual fear conditioning and normal
hippocampal network excitability after mild to moderate TBI (15).
The current study includes additional experiments that explore
the dependence of BCAA therapy on the time course, method and
amount of BCAA administration, and also the duration of action
of BCAA therapy.
Our data establish that BCAA therapy is required for at least
five consecutive days at a dose of either 100 mM in ad libitum
drinking water or 0.26 g/kg via oral gavage, to restore normal fear
conditioning. Furthermore, stopping therapy, after 5 days, results
in a functional relapse to levels seen in untreated injured ani-
mals. These results suggest the persistence of a functional deficit
after TBI, which ongoing BCAA supplementation can successfully
treat.
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FIGURE 3 | Dosage effects of BCAA treatment. (A) BCAA supplemented
water administered ad libitum for 10 days after injury produced significant
improvement in conditioned fear responses compared to brain-injured mice
given untreated water for 10 days. Mice receiving BCAA supplemented
water for 5 days, then untreated water for 5 days, did not show significant
improvements in conditioned fear responses and were not significantly
different from injured mice receiving no treatment (*P <0.05). These
results suggest that BCAAs need to be continuously administered in order
to maintain cognitive improvement after brain injury. (B) BCAA
supplemented water administered ad libitum at 50 and 100 mM for 5 days.
Significant cognitive improvement in brain-injured mice was produced with
100 mM BCAA supplemented water, but not with 50 mM BCAA
supplemented water (*P < 0.05 and **P <0.01). Abbreviations describing
treatment received by injured animals prior to testing: 5d− and 10d−,
drinking water without BCAAs for 5 and 10 days, respectively; 10d+,
100 mM BCAA supplemented drinking water for 10 days; 5d+|5d−, 100 mM
BCAA supplemented drinking water for 5 days, followed by 5 days with
plain water; 5d−, no treatment for 5 days; 5d+ 100 mM, 100 mM BCAA
supplemented drinking water for 5 days; 5d+ 50 mM, 50 mM BCAA
supplemented drinking water for 5 days.
Our results complement and expand those of Aquilani et al.
who found modest reduction in levels of disability in severely
brain-injured patients after intravenous administration of BCAAs
(17, 18). Enteral administration of BCAA therapy confers sev-
eral benefits including slower BCAA uptake (absorption), which
does not saturate CNS BCAA transporters on the blood–brain
barrier. Dietary therapy is also advantageous in that patients
recovering from TBI, and mild TBI in particular, do not require
hospitalization and intravenous access for BCAA administration.
This enduring cognitive dysfunction may be due to alterations
in hippocampal metabolism after TBI, with an associated reduc-
tion in BCAA concentrations (15). Approximately 50% of brain
glutamate and 40% of the releasable synaptic glutamate contain
BCAA-derived nitrogen (20). It is possible that BCAA supplemen-
tation improves hippocampal functioning by restoring pools of
releasable vesicular glutamate and GABA. Measurements of gluta-
mate and GABA in injured brain have not been able to distinguish
synaptic pools of glutamate and GABA from the much larger
and independent metabolic pools of glutamate and GABA (15).
A recent report using cultured cerebellar neurons, however, sug-
gests that at least one of the BCAAs, valine, does indeed become
incorporated into the glutamate found in synaptic vesicles (24).
Our results indicate that BCAAs must be consumed continuously
for at least 5 days after injury to restore cognitive function, and
that ongoing supplementation is necessary to maintain this cog-
nitive recovery. These findings are consistent with the hypothesis
that replenishment of synaptically releasable glutamate and GABA
may be the primary mechanism by which normal hippocampal
functioning is restored.
In addition to its effects in the hippocampus, BCAA therapy
may have widespread effects in other brain networks as well,
such as those involved in sleep and wakefulness. A recent study
from our laboratory demonstrated that BCAA supplementation
improved wakefulness after FPI, acting at least in part via orexin
neurons in the lateral hypothalamus (16). BCAA therapy also
restored EEG rhythms indicative of normal wakefulness, suggest-
ing that BCAA effects are likely not restricted to the hippocampus
alone (16).
Our results from this preclinical mouse model suggest that
BCAA therapy has great potential as a treatment for the neu-
rocognitive deficits from TBI. Such therapies are much needed,
as there are currently no pharmacological interventions available.
Advantages of this therapy include enteral and parenteral admin-
istration and being able to commence therapy 48 h after brain
injury, thereby qualifying BCAA treatment as a neurorestorative
rather than a neuroprotective therapy. Neurorestorative therapies
have a significant advantage because they can be offered after an
individual has sustained a TBI.
Decreased BCAA concentrations have also been reported in
humans after TBI and parenteral BCAA administration improved
disability outcomes after severe TBI (17, 22, 23). BCAAs have been
used therapeutically for a variety of other neurological condi-
tions and overall well tolerated and associated with minimal to
no side effects (21, 25, 26). In summary, BCAAs are a potential
neurorestorative therapy for TBI and these data could inform the
development of human clinical trials.
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